Rivaroxaban-Related Traumatic Large Subcutaneous Hematoma in the Calf Requiring Surgical Repair in an Elderly PatientFunding None.
10. Mai 2020 (online)
The direct oral anticoagulant (DOAC) rivaroxaban (RIV) is a factor Xa inhibitor which is mainly used for the prevention of atrial fibrillation-induced ischemic stroke. Recently, RIV has also been used in cases of aneurysm-associated chronic disseminated intravascular coagulation (DIC), although this application is off-label. The use of DOACs is associated with uncontrollable hemorrhagic complications and even death.   Regarding the site of RIV-related bleeding complications, the J-ROCKET AF study in Japan reported bleeding in the upper gastrointestinal tract tract (6%), intracranial (5%), intraarticular (4%), and intraocular (3%) regions. Therefore, at the time of DOAC-related major bleeding complications, rapid and reliable reversal of the anticoagulant effect is required, particularly in patients with life-threatening intracranial hemorrhage.  In such cases, 4-factor prothrombin complex concentrate (4F-PCC) has been employed,   though andexanet alfa was recently developed for reversal of factor Xa inhibitors. Here, we report a case of traumatic severe subcutaneous bleeding in the calf of an elderly patient treated with RIV for chronic DIC due to thoracoabdominal aneurysms.
An 84-year-old female who had undergone thoracic endovascular aortic repair for an aortic dissected aneurysm was suffering from chronic DIC. After being treated with intravenous and subcutaneous heparin, the patient became intolerant of subcutaneous heparin administration because of pain and was transitioned to oral RIV prior to discharge from hospital. Outpatient clinic assessment showed that her DIC was well controlled by the treatment with RIV (15 mg/d) and tranexamic acid (TXA; 1,500 mg/d). One year later, she suffered an accidental blunt injury to her right calf at home caused by a plastic costume case. She was hospitalized 3 hours later, at which point her hemoglobin (Hb) level was 9.0 g/dL, platelet count of 90 K/μL, serum blood urea nitrogen 24.4 mg/dL (reference; 7.8–18.9), and creatinine 0.89 mg/dL (reference; 0.45–0.82); prothrombin time (PT) was 29.7% (reference: 80–100%), PT-international normalized ratio 2.07 (reference: 0.9–1.1), and activated partial thromboplastin time 40.5 seconds (control: 27.9 seconds). Six hours after the injury, contrast-enhanced computed tomography (CT) scanning showed a large subcutaneous hematoma in her right calf causing swelling to 1.8-fold the width of the left calf ([Fig. 1]). No arterial damage was detected and palpation of the dorsal artery of the right foot was possible. The bleeding was not considered to be life-threatening and the patient was kept under observation. On the following morning (Day 2 of hospitalization), RIV was discontinued but TXA treatment was maintained. Her Hb level dropped to 6.3 g/dL and a marked exacerbation of the hematoma size was observed. Although the patient received packed red blood cells (PRBC; four units) and fresh frozen plasma (FFP; four units), the skin over the hematoma developed large bullae, which became necrotized probably due to disruption of the perforating branch artery that provides nutrients to the cutaneous tissue. On Day 3, the Hb level remained at 7.3 g/dL, necessitating the administration of additional PRBC (two units) and FFP (two units). On Day 4, since the subcutaneous hematoma was thought to be further increased in size, treatment with PRBC (four units) and FFP (four units) was given combined with 4F-PCC (30 IU/kg, total: 1,000 IU). On Day 5, the patient's Hb level was stable at 9.3 g/dL and complete hemostasis was assumed to be achieved. The patient subsequently required plastic surgery to repair the necrotized and blackened skin on the right calf ([Fig. 2A]). On Day 13, debridement of the tissue was performed and artificial dermis was used to cover the wound followed by permanent skin grafting on Day 35. During this period, RIV was discontinued for 40 days; DIC was effectively managed with TXA alone and no thrombotic events occurred. The patient was able to walk and was discharged on Day 42. On day 50, successful skin grafting was confirmed ([Fig. 2B]).
DOAC-related major or severe bleeding is defined as hemodynamic instability, a fall in Hb level of 2 g/dL, or hemorrhage requiring blood transfusion. The case reported here fits these criteria. The in vivo half-life of RIV is approximately 5 to 13 hours, and on the day of the injury, the patient had taken RIV (15 mg) and TXA (500 mg) in the morning before suffering the calf trauma. Six hours after the accident, CT scanning showed that the right calf had swollen to approximately twice its normal width due to the presence of a severe subcutaneous hematoma. RIV was withdrawn the next day but the bleeding continued and did not seem to be responding to the management with PRBC and FFP alone. In reversing DOACs, limited effectiveness of FFP was previously reported while effectiveness of PCC was established. In our case, initially we were hesitant to give PCC considering its thrombotic risk. Theoretically, complete metabolism of RIV can be achieved in less than 3 days from its half-life (5–13 hours) in an individual with normal renal function. Though PCC was thought to be clinically effective because of no more Hb drop, administration of it on Day 4 was late as an anti-RIV. Thus, bleeding cessation might have occurred due to improved clotting in the setting of chronic DIC. Anyway, eventually the case reported here required repair of the damaged skin. Optimal timing of the PCC administration is critical but remains controversial   due to the risk of thrombotic events, which may develop within 14 days of PCC use, though in this case, no thrombotic events occurred. In summary, to prevent RIV-related severe bleeding complications and to limit the adverse consequences, timely administration of PCC or a new agent such as andexanet alfa without relying on FFP is important to establish hemostasis.
The work was performed in accordance with the Declaration of Helsinki.
- 1 Vimalesvaran K, Dockrill SJ, Gorog DA. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vasc Health Risk Manag 2018; 14: 13-21
- 2 Koba S, Yamaguchi T, Miki K, Makihara H, Imashuku S. Management of chronic disseminated intravascular coagulation associated with aortic aneurysm/dissection. Case Rep Hematol 2019; 2019: 6204652
- 3 Beynon C, Potzy A, Sakowitz OW, Unterberg AW. Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: a dangerous combination?. Clin Neurol Neurosurg 2015; 136: 73-78
- 4 Grandhi R, Newman WC, Zhang X. , et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg 2015; 84 (06) 1956-1961
- 5 Majeed A, Ågren A, Holmström M. , et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
- 6 Hori M, Matsumoto M, Tanahashi N. , et al; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 2012; 76 (09) 2104-2111
- 7 Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care 2018; 6: 34
- 8 Connolly SJ, Crowther M, Eikelboom JW. , et al; ANNEXA-4 Investigators. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
- 9 Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants?. Kardiol Pol 2019; 77 (01) 3-11
- 10 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
- 11 Levy JH, Moore KT, Neal MD. , et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. J Thromb Haemost 2018; 16 (01) 54-64